Last reviewed · How we verify

abatacept infusion

University of Minnesota · FDA-approved active Small molecule Under review

abatacept infusion is a T-cell costimulation inhibitor Small molecule drug developed by University of Minnesota. It is currently FDA-approved for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.

Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.

Abatacept is a protein-based inhibitor of the T-lymphocyte activation antigen CD86, used to treat various conditions including rheumatoid arthritis and chronic cytopenia in CTLA4 haploinsufficiency. It is administered via infusion as part of clinical trials for these conditions, with its efficacy and safety being studied in randomized, double-blind trials.

At a glance

Generic nameabatacept infusion
SponsorUniversity of Minnesota
Drug classT-cell costimulation inhibitor
TargetCD80/CD86
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Abatacept (CTLA4-Ig) works by interrupting the second signal required for full T-cell activation. It binds to CD80 and CD86 molecules on antigen-presenting cells, preventing their interaction with CD28 on T cells. This selective costimulation blockade reduces proliferation and activation of T cells, leading to decreased production of inflammatory cytokines and reduced autoimmune responses.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about abatacept infusion

What is abatacept infusion?

abatacept infusion is a T-cell costimulation inhibitor drug developed by University of Minnesota, indicated for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.

How does abatacept infusion work?

Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.

What is abatacept infusion used for?

abatacept infusion is indicated for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Systemic lupus erythematosus.

Who makes abatacept infusion?

abatacept infusion is developed and marketed by University of Minnesota (see full University of Minnesota pipeline at /company/university-of-minnesota).

What drug class is abatacept infusion in?

abatacept infusion belongs to the T-cell costimulation inhibitor class. See all T-cell costimulation inhibitor drugs at /class/t-cell-costimulation-inhibitor.

What development phase is abatacept infusion in?

abatacept infusion is FDA-approved (marketed).

What are the side effects of abatacept infusion?

Common side effects of abatacept infusion include Infection (upper respiratory, urinary tract), Headache, Nausea, Dizziness, Hypertension, Serious infections.

What does abatacept infusion target?

abatacept infusion targets CD80/CD86 and is a T-cell costimulation inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing